CTBP1 and cancer: Targeting the Rossmann fold of CtBP1/BARS with small molecules has been proposed as a potential anti-cancer therapy, aiming to disrupt its interaction with transcription partners and protein complexes involved in mitotic entry and transcriptional activities.